Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.
CNS Pharmaceuticals reports news about its clinical-stage biotechnology business and its strategy to build a neurology and oncology pipeline. Company updates commonly address anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system, including TPI 287 and Berubicin, as well as clinical-data presentations and regulatory-development planning.
Recurring developments also include executive leadership changes, pipeline prioritization, business-development strategy, financial results, capital-allocation commentary, shareholder voting matters, governance updates and capital-structure disclosures tied to its Nasdaq-listed common stock.
CNS Pharmaceuticals (NASDAQ: CNSP) announced that its European manufacturer, BSP Pharmaceuticals, has started producing its lead drug candidate, Berubicin, for treating glioblastoma multiforme (GBM), a lethal brain cancer. CEO John Climaco highlighted significant progress towards filing an IND by the end of Q4 2020 and initiating a U.S. Phase 2 trial in Q1 2021. The company implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks. Additionally, the FDA granted Berubicin Orphan Drug Designation, which may provide the company with market exclusivity upon approval.
CNS Pharmaceuticals (NASDAQ: CNSP) announced a critical achievement in the manufacturing of Berubicin, its lead cancer treatment. Partner NCK A/S has received a Certificate of Analysis for the Active Pharma Ingredient, which allows for large-scale production. This development is expected to ensure drug availability for upcoming Phase 2 clinical trials for glioblastoma, anticipated to start in Q1 2021. CNS holds exclusive rights to Berubicin and aims to advance treatment options for aggressive brain cancers, following promising earlier trial results.
CNS Pharmaceuticals (NASDAQ: CNSP) has partnered with Image Analysis Group (IAG) to enhance imaging services for its upcoming Berubicin clinical trials. The partnership aims to leverage IAG's advanced AI-driven methodologies for real-time patient response analysis during the trials focused on glioblastoma multiforme (GBM). CNS anticipates launching Phase II trials of Berubicin in adults by early 2021. Previous Phase 1 trials showed a 44% disease control rate, though results may not guarantee future efficacy. This collaboration represents a significant step in CNS's preparation for clinical advancements.
CNS Pharmaceuticals (NASDAQ: CNSP) announced that CEO John Climaco will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020, at 10:00 AM EDT. The company is focused on developing treatments for central nervous system cancers, with its lead candidate, Berubicin, showing promising results in a completed Phase 1 trial for glioblastoma multiforme. A replay of the presentation will be available on the company’s website for 90 days following the event.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that CEO John Climaco will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 16, 2020, at 9:30 AM EDT. The conference will feature management holding 1-on-1 meetings with investors. CNS is focused on developing treatments for central nervous system cancers. Its lead drug candidate, Berubicin, targets glioblastoma multiforme, with a promising Phase 1 trial showing a 44% disease control rate. A Phase 2 trial in the U.S. is expected to commence by the end of 2020.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced advancements in the U.S. manufacturing of Berubicin, its lead drug candidate for treating CNS cancers. Engaging Pharmaceutics International, Inc. and BSP Pharmaceuticals, the company aims to mitigate COVID-19-related risks. Key milestones include completed synthesis of the active pharmaceutical ingredient (API) and a successful laboratory simulation of the lyophilization cycle. The company anticipates starting Berubicin production in Q3 2020 and plans to submit an IND to the FDA in Q4 2020, following recent achievements in clinical trial preparations.
CNS Pharmaceuticals (NASDAQ: CNSP) announced the appointment of Dr. Patrick Wen, a neurology professor at Harvard Medical School and director at Dana-Farber Cancer Institute, to its Science Advisory Board. Dr. Wen's expertise in neuro-oncology is expected to enhance CNS's efforts in advancing its lead drug candidate, Berubicin, targeting glioblastoma. The company is preparing for Phase I pediatric and Phase II adult trials in Poland and the U.S. Additionally, CNS has engaged Pharmaceutics International and BSP Pharmaceuticals for Berubicin production, ensuring localized availability for clinical use.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) has announced significant progress in the development of its lead drug candidate, Berubicin, for glioblastoma multiforme (GBM). The company plans to submit an Investigational New Drug (IND) application to the FDA and commence Phase 2 clinical trials in early 2021. CNS has partnered with Worldwide Clinical Trials for trial management and Berry Consultants for statistical guidance. Recently, Berubicin received Orphan Drug Designation from the FDA, providing benefits during development. The company is also advancing its manufacturing capabilities for Berubicin.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced the engagement of Worldwide Clinical Trials as its contract research organization (CRO) for upcoming Berubicin clinical trials. This partnership aims to enhance trial design and execution for Berubicin, the company's lead candidate targeting glioblastoma multiforme. CNS has also enlisted Pharmaceutics International and BSP Pharmaceuticals for Berubicin production, implementing a dual-track strategy to mitigate risks. The company expects to commence Phase 2 trials in adults and a Phase 1 trial in pediatric patients by the end of 2020.
CNS Pharmaceuticals announces a shareholder webinar on August 13, 2020, at 4:30 PM ET. CEO John M. Climaco will discuss business developments, including the progress of CNS's lead candidate Berubicin and novel DNA-binding agent WP1244, alongside their development agreement with WPD Pharmaceuticals for WP1122. CNS specializes in treatments for brain tumors, particularly targeting glioblastoma, considered incurable. The event aims to update shareholders on significant advancements and strategies of the company.